Synaptogenix Inc (SNPX) - Total Liabilities
Based on the latest financial reports, Synaptogenix Inc (SNPX) has total liabilities worth $1.83 Million USD as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Synaptogenix Inc cash flow conversion to assess how effectively this company generates cash.
Synaptogenix Inc - Total Liabilities Trend (2018–2024)
This chart illustrates how Synaptogenix Inc's total liabilities have evolved over time, based on quarterly financial data. Check Synaptogenix Inc asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Synaptogenix Inc Competitors by Total Liabilities
The table below lists competitors of Synaptogenix Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
PicoCELA Inc. American Depositary Shares
NASDAQ:PCLA
|
USA | $624.90 Million |
|
EA Holdings Bhd
KLSE:0154
|
Malaysia | RM5.51 Million |
|
Paras Petrofils Limited
NSE:PARASPETRO
|
India | Rs217.00K |
|
Close Brothers Group plc
LSE:CBG
|
UK | GBX10.82 Billion |
|
Maha Rashtra Apex Corporation Limited
NSE:MAHAPEXLTD
|
India | Rs769.87 Million |
|
Critical Minerals Group Ltd
AU:CMG
|
Australia | AU$3.78 Million |
|
Bitros Holding S.A
AT:MPITR
|
Greece | €163.83 Million |
Liability Composition Analysis (2018–2024)
This chart breaks down Synaptogenix Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Synaptogenix Inc (SNPX) market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 20.51 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.10 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.09 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Synaptogenix Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Synaptogenix Inc (2018–2024)
The table below shows the annual total liabilities of Synaptogenix Inc from 2018 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $10.96 Million | +98.16% |
| 2023-12-31 | $5.53 Million | +73.17% |
| 2022-12-31 | $3.19 Million | +60.06% |
| 2021-12-31 | $1.99 Million | +23.72% |
| 2020-12-31 | $1.61 Million | +236.60% |
| 2019-12-31 | $479.06K | -83.80% |
| 2018-12-31 | $2.96 Million | -- |
About Synaptogenix Inc
TAO Synergies Inc. operates as a biopharmaceutical company. The company is primarily focused on developing a product platform based upon Bryostatin-1, for the treatment of Alzheimer's disease (AD), which is in the clinical testing stage. It is also evaluating potential therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X synd… Read more